Gilead Sciences Inc. (GILD): Framing the upcoming oral α4β7 data in ulcerative colitis

GILD will present Phase 2 SWIFT (n=228) induction data for oral α4β7 integrin inhibitor emvigrast in moderate-to-severe ulcerative colitis at United European Gastroenterology Week on Oct. 19. The primary endpoint is clinical response at Week 12, with clinical remission a key secondary endpoint. Our KOL diligence suggests Takeda's Entyvio (vedolizumab), which targets the same α4β7 pathway, provides the most relevant benchmark. More broadly, we note a highly competitive landscape - ABBV's Skyrizi (IL-23) and Rinvoq (oral JAK) have demonstrated placebo-adjusted remission rates of roughly 14% and 20-30%, and emerging oral agents such as ABBVX's obefazimod and JNJ's icotrokinra continue to advance. In this context, we view a 15-20% placebo-adjusted clinical remission rate as the bar for a competitive result and note that expectations are positive given GILD's recent commentary. Beyond efficacy, physicians are also focused on whether an oral α4β7 inhibitor can replicate the favorable safety